Policy improvement and expected Sinopharm synergies support the Buy thesis on AmoyDx

Overview

This report is Goldman Sachs' conference takeaway following AmoyDx's participation in China Healthcare Corporate Day 2026. The core discussion focuses on three main themes: marginal improvement in China's oncology precision testing policy environment in 2026, the company's potential transfer of control to Sinopharm, and operating guidance and growth outlook for 2026-2028.

Core views

The report believes AmoyDx's medium- to long-term thesis remains positive. The implementation of in-hospital molecular pathology reimbursement catalogs should help standardize in-hospital oncology genetic testing compliance and drive sample flow-back from outside hospitals to hospitals; anti-corruption measures have temporarily slowed new product hospital entry and customer interactions, but may also strengthen sample flow-back in the long run. After the potential transfer of control, the current management team will continue to participate steadily in operations, and Sinopharm is expected to provide synergies in hospital access, MNC pharma CDx collaboration, Belt and Road market channels, and regulatory communication.

Analysis framework

The report combines management meeting takeaways, company guidance, industry penetration judgments, policy change analysis, and two-stage DCF valuation to assess the impact of policy, change in control, business growth, and valuation on the investment view for AmoyDx.

Methodology notes

• Valuation methodTwo-stage DCF

  12-month target price

  The Rmb29 target price is based on a two-stage DCF valuation, assuming a discount rate of 10.5% and a terminal growth rate of 3%, with the valuation method and assumptions unchanged.

• Factor analysisGS Factor Profile

  Growth, financial returns, valuation multiples, and composite factors

  The Goldman Sachs Factor Profile provides investment context for individual stocks by comparing their growth, financial returns, and valuation multiples with the market and industry peers.

• Event assessmentM&A Rank

  Framework for probability of potential acquisition

  Goldman Sachs uses an M&A framework to assess the probability that a company could become an acquisition target; this report discloses the framework for reference, but its core investment conclusion mainly comes from fundamentals, policy, and valuation analysis.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AmoyDx (300685.SZ)

  Research target

  Strengths

  The company is a leading participant in China's oncology companion diagnostics industry, with strong in-hospital positioning and benefits from sample flow-back; the pharma CDx business is supported by orders for relatively fast growth; potential Sinopharm synergies could enhance hospital access, MNC pharma cooperation, and overseas channels.

  Weaknesses

  Average ex-factory price is expected to decline by 10%-20% due to repricing; international business has been relatively muted in recent years due to team restructuring and JPY depreciation; short-term anti-corruption measures have slowed new product hospital entry and customer interactions.

  Comparison

  Goldman Sachs rates it relative to other companies in its China healthcare coverage universe and believes its 1-year forward PE is in the bottom quartile of the past five years, making the valuation attractive.

  Risks

  Intensifying industry competition, regulatory changes in mainland China and overseas, VBP implementation, pricing pressure, weaker-than-expected synergies from the change in control, and a slower-than-expected overseas recovery.

Key data

• Report date2026-06-29The report was published at 11:22 AM CST on 29 June 2026.
• RatingBuyThe report explicitly states that it maintains a Buy rating on AmoyDx.
• 12-month target priceRmb29Based on a two-stage DCF valuation, with a 10.5% discount rate and 3% terminal growth rate.
• Disclosed current priceRmb16.18The company-specific disclosure lists AmoyDx's price at Rmb16.18.
• Potential upsideApproximately 79%Roughly calculated based on the Rmb29 target price and the Rmb16.18 current price.
• Change-of-control valuationClose to Rmb8.3bnThe transaction valuation for transferring control to Sinopharm is close to Rmb8.3bn, implying a premium to the current share price.
• 2026 revenue guidanceGrowth of 5%-10%The company maintains its 2026 revenue growth guidance unchanged.
• 2026 net profit targetRmb400mnCompared with Rmb360mn in 2025.
• Pharma CDx business growthMore than 15% annual growthManagement expects sustainable annual growth above 15% based on existing orders.
• 2027-2028 revenue targetAround 10% growthProfit growth is expected to outpace revenue, supported by operating leverage, expense optimization, and lower upstream NGS costs.
• Oncology companion diagnostics penetration13% in 2020 to 45% by 2031EGoldman Sachs expects long-term improvement in oncology companion diagnostics penetration in China.
• Overseas revenue contributionMore than 20% by 2031EGoldman Sachs expects overseas business to contribute more than 20% of revenue by 2031E.
• Ex-factory price impactDown about 10%-20%Management expects the latest repricing to lower the company's average ex-factory price by about 10%-20%.
• VBP timing viewNot to be launched within the next three yearsManagement believes only about one-third of provinces currently include the relevant tests in reimbursement, and expects VBP will not be launched within three years.

Impact & implications

If policy continues to promote compliant in-hospital testing and sample flow-back, AmoyDx's in-hospital channel advantages may be amplified; if Sinopharm synergies are successfully realized, the company could gain incremental support in hospital access, multinational pharma CDx collaboration, and overseas channel expansion. On valuation, the target price still implies substantial upside versus the current price, but price cuts, industry competition, regulatory changes, and VBP remain the main uncertainties.

Risks

• Intensifying industry competition may compress growth and profitability.
• Regulatory changes in mainland China or overseas may affect product access, reimbursement, and commercialization pace.
• If VBP is implemented earlier than expected, it may bring pressure on pricing and margins.
• Anti-corruption measures may continue to slow hospital access and customer interactions in the short term.
• Repricing that lowers average ex-factory prices by about 10%-20% may affect revenue quality.
• Overseas business recovery depends on team restructuring, Sinopharm channel support, and the FX environment.

What to watch

• The pace of recovery in in-hospital testing and sample flow-back in 2H26.
• Actual orders and pricing performance after provincial molecular pathology reimbursement catalogs are implemented.
• Progress of the Sinopharm control transaction and management stability.
• Realization of Sinopharm synergies in hospital access, MNC pharma CDx cooperation, and Belt and Road market channels.
• Whether the pharma CDx business can sustain annual growth above 15%.
• Volume ramp-up of PD-L1 CDx products and the launch pace of new overseas products.
• Changes in VBP coverage, expansion of reimbursing provinces, and regulatory policy developments.